middle.news
How Will Recce’s A$15.8M Raise Propel Its Phase 3 Trials Forward?
10:21am on Tuesday 3rd of June, 2025 AEST
•
Healthcare
Read Story
How Will Recce’s A$15.8M Raise Propel Its Phase 3 Trials Forward?
10:21am on Tuesday 3rd of June, 2025 AEST
Key Points
Completion of A$15.8 million capital raising including private placement and entitlement offer
A$7.4 million raised from shortfall placement to institutional and sophisticated investors
Funds to support Phase 3 clinical trials in Indonesia and Australia for diabetic foot and skin infections
Advancement of Investigational New Drug Application to US FDA
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE